Offshore Public Offerings and Capital Markets

Ke regularly advises companies on offshore listings and other capital market financings; his representations amount to an aggregate financing size of over US$20 billion, including:

Life Sciences, Medical and Healthcare:

• Companies: Jiangxi Biology; TenNor Therapeutics; Cofoe Medical; Diagens Biotech; Distinct Healthcare; BenQ BM Holding; Vigonvita Life Sciences; TransThera Sciences (IPO and follow-on offering); INT Medical Instruments (follow-on offering); TYK Medicines; Sunho Biologics; RemeGen; Akeso Biopharma; Yonghe Medical; Adlai Nortye (Nasdaq); Beauty Farm; Shanghai Bio-heart; Luzhu Biotech; Cryofocus Medtech; Sipai Health; 3D Medicines; Gaush Meditech; Jenscare Scientific; Rainmed; Gushengtang; Acotec Scientific; Brii Biosciences; Keymed Biosciences; Jacobio Pharmaceuticals; Simcere Pharmaceutical; Honliv Healthcare; Hygeia Healthcare; Peijia Medical; Shanghai Kindly Medical Instruments; Pharmaron; Aesthetic Medical International (Nasdaq); Hua Medicine; ShangPharma (NYSE); Viva Biotech; Shanghai Haohai Biological; 3S Bio (Nasdaq); Phoenix Healthcare, and Mabgeek Biotechnology (ongoing); Sinotau Pharmaceutical (ongoing); Genecast Biotech (ongoing); Shanghai Cell Therapy Group (ongoing); Zephyrm Biotech (ongoing)
• Underwriters and Sponsors: Metis TechBio; Ribo Life Science; Bayzed Health Group Inc; Qyuns Therapeutics; Shanghai HeartCare Medical; Wuxi AppTech (NYSE), and Neautus Traditional Chinese Medicine (ongoing)

TMT:

• Companies: Synyi.ai (ongoing); AICT (ongoing); Taimei Medical Technology; Qunabox Group Limited; Folangsi; UBOX Online; UP Fintech (Nasdaq); Youku.com Inc. (NYSE); RenRen.com Inc. (NYSE); Yeahka; eHi Car Services (NYSE); and Montage (Nasdaq)
• Underwriters and Sponsors: Roborock Tech (ongoing); Metis TechBio; Time Interconnect (follow-on offering); Shouhui Group; UP Fintech (Nasdaq, follow-on offering); Shanghai Voicecomm Infotech; Fourth Paradigm; Huafang Group; GDS; 58.com (NYSE); Zhongguancun Science-Tech Leasing; FingerTango; Digital Hollywood; Leju Holdings (NYSE); Jupai Holdings (NYSE); Tarena Technologies (Nasdaq); Zero2IPO; and Chen Lin Education Group

Other:

• Shenzhen Woer; Eastroc Beverage (underwriters); Forest Cabin (underwriters); Laopu Gold; Tiantu Capital; CNGR Advanced Material; Shuangdeng Group; Hainan Drinda New Energy; REFIRE Group (IPO and follow-on offering); Ruichang International; Chenghe Acquisition II Co. (NYSE); China CITIC Bank; China Construction Bank Corporation; Dexin China; Bank of Qingdao; Hengxing Gold; China Polymetallic Mining; China Real Estate Information Corporation (Nasdaq); Yuzhou Group; Crystal River Capital (NYSE, underwriters); and NorthStar Realty Finance Corp. (NYSE)

M&A and Going-Private Transactions:

Ke has advised numerous well-known public companies on mergers and acquisitions and going-private transactions, including:

M&A:

• Tiantu Capital in the approximately US$226 million sale of its entire interest in Yoplait China to Kunshan Nuoyuan Ruiyuan Management Consulting Co., Ltd.
• Tianhui Biotech in the US$75 million NewCo model investment with Oramed
• Acotec Scientific in its approximately US$520 million voluntary partial offer by Boston Scientific
• Viva Biotech in its US$387.3 million acquisition of Langhua Pharmaceutical and US$135.4 million share placement
• TTM technologies (NASDAQ: TTMI), a leading global printed circuit board (PCB) manufacturer, on the US$660 million divestiture of its four China manufacturing plants comprising substantially all of the assets of its Mobility business, to AKM Meadville Electronics (Xiamen) Co., Ltd.
• the management consortium in the US$200 million leveraged acquisition of ATA Online (Beijing) Education Technology Co., Ltd. (ATA Online), a wholly owned subsidiary of ATA Inc. (ATAI)
• the Meinian buyer consortium in a competing going private bid against management for Chinese healthcare Company iKang Healthcare Group (NASDAQ: KANG)
• Sinobioway Biomedicine as buyer consortium in a competing going private bid of Sinovac (NasdaqGS: SVA)
• Pudong Science and Technology Investment (PDSTI) in its US$100 million investment in Icon Aircraft, Inc.
• BGI-Shenzhen in its $117 million acquisition of Complete Genomics (NASDAQ: GNOM) through a tender offer (first tender offer acquisition of a US-based public company by a Chinese company)
• Jiangsu Phoenix Education Publishing Co., Ltd. in its US$80 million acquisition of the assets relating to the children's book business of Publication International Ltd. (PIL) and PIL's subsidiaries
• DaimlerChrysler in its US$7.4 billion sale of Chrysler LLC to Cerberus

Going-Private:

• Zhaopin (buyer consortium); Homeinns (company); Bona Film (Goldstone Investment as a member of buyer consortium); Luoxin Pharmaceuticals (buyer consortium); ShangPharma (special committee); Feihe (special committee); China Real Estate Information Corporation (the company); China XD Plastics (the company); SORL (the company), and Highpower (Essence International as part of buyer consortium)

PE/VC Investments:

Ke has advised on numerous private equity and venture capital transactions in the life sciences, medical and healthcare industries as well as other industries, including:

• Distinct Healthcare; Brii Biosciences; Keymed Biosciences; Acotec Scientific; Peijia Medical; Medbanks Network Technology; Ansun Biopharma; Viva Biotech; Aesthetic Medical International; Livzon Pharmaceutical; 3D Medicines, and Zhongmei Healthcare Group

Other Industries:

• a consortium led by Capital Group and Blackstone in the US$600 million pre-IPO investment in Dili Group Holdings
• Och-Ziff Capital Management Group as part of a consortium led by Royal Bank of Scotland plc. in an investment in Bank of China